Back to Acceleration Radar
PGNYProgyny Inc
Health Care · Misc Health and Biotechnology Services · Mid
$28.97−0.52%
As of 23 Oct 2026Mkt cap $2.0B
Stage 13
WAIT
Fundamentals
47.2/75
Technical
7.6/15
Independent
54.8/90
GCAE viewtechnical state requires waiting rather than entering now
Price
- 1M
- +11.6%
- 3M
- −8.3%
- 6M
- +59.4%
- 1Y
- +51.1%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 31.5xHist median 34.3x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 14.6x
- FCF yield
- 6.9%
Quality
- ROIC
- 14.7%
- Operating margin
- 5.8%
- FCF margin
- 14.9%
- Current ratio
- 2.7x
Growth
- Revenue growth
- +10.4%Latest FY YoY
- Revenue CAGR
- +26.7%
- EPS CAGR
- −0.4%
- FCF CAGR
- +68.3%
Capital
- Share-count trend
- −5.5%3Y annualised
- Net cash
- $85M-0.4x OCF
Annual trend
- CAGR 2021–2025
- +26.7%
- Latest · 2025
- $1B
- YoY
- +10.4%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
technical state requires waiting rather than entering now
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded